Compare Argo Pantes Tbk (ARGO) vs Dharma Polimetal Tbk. (DRMA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Argo Pantes Tbk vs Dharma Polimetal Tbk. — how do they compare? Argo Pantes Tbk trades at Rp1,160 (market cap 3.7T, 117.3K 24h volume), while Dharma Polimetal Tbk. trades at Rp985 (market cap 4.64T, 531.1K 24h volume). The key difference: Dharma Polimetal Tbk. is the larger of the two by market cap, and Dharma Polimetal Tbk. is more actively traded (531.1K versus 117.3K). Which is the better fit depends on your goals.
| ARGO | DRMA | |
|---|---|---|
Market Cap | 3.7T | 4.64T |
Volume | 117.3K | 531.1K |
Lot | 1.17K | 5.31K |
Turnover | 136.3M | 523.32M |
Average Price | 1,161.99 | 985.35 |
Value | 136.3M | 523.32M |
Indicative Equilibrium Price | — | 985 |
Indicative Equilibrium Volume | — | 125 |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Argo Pantes Tbk
PT Argo Pantes Tbk (the Company) was established on July 12, 1977 based on Deed No. 30 of Darwani Sidi Bakaroedin, S.H., Notary in Jakarta. PT Argo Pantes, one of the largest integrated textile companies in Indonesia. The Company achieved ISO 9002 certification in 1997 from SGS, Indonesia, and is the flagship Company of the Argo Manunggal Group. To date, the Companys export sales has reached 80% from more than 200 international customers in 40 countries worldwide, much as : Levis, Liz Claiborne, Marks & Spencer. NIKE, NEXT, GAP, and Tommy Hilfiger.
Read more on ARGO →About Dharma Polimetal Tbk.
PT Dharma Polimetal Tbk (“the Company”) was established in the Republic of Indonesia on 27 March based on Notarial deed No. 74 of Rukmasanti Hardjasatya, S.H. The Company begin opertions on year 1989 and commenced its commercial activities since 1990. The Company’s Majority shareholder is PT Dharma Inti Anugerah, established in Republic Indonesia on 20 November 2003.
Read more on DRMA →
